TD Cowen lowered the firm’s price target on Agilon Health (AGL) to $1 from $4 and keeps a Hold rating on the shares. The firm noted they pre-announced a material revenue/medical margin/adj EBITDA miss primarily due to RAF revisions and unfavorable PYD. The company withdrew its 2025 guidance and announced its CEO stepped down and is searching for a replacement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health Reports Q2 2025 Results Amid Leadership Change
- Agilon Health downgraded to Neutral from Buy at Citi
- Optimistic Buy Rating for Agilon Health Amid Strategic Initiatives and Future Prospects
- Agilon Health’s Hold Rating Amid CEO Resignation and Earnings Shortfall
- Agilon Health: Hold Rating Amid Leadership Uncertainty and Financial Challenges